Rocket Pharmaceuticals (RCKT) Capital Leases (2020 - 2026)
Rocket Pharmaceuticals (RCKT) posted Capital Leases of $19.3 million for Q1 2026, little changed sequentially from $19.4 million in Q4 2025, and little changed YoY from $19.4 million in Q1 2025.
Rocket Pharmaceuticals (RCKT) Capital Leases (2020 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Capital Leases for 7 years, with the latest figure at $19.3 million in Q1 2026.
- Quarterly Capital Leases changed 0.18% year-over-year to $19.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.3 million (changed 0.18% YoY) and the FY2025 annual result came in at $19.4 million, changed 0.11% from the prior year.
- Capital Leases held at $19.3 million in Q1 2026 per RCKT's latest filing, from $19.4 million in the prior quarter.
- Over five years, Capital Leases peaked at $19.4 million in Q4 2024 and troughed at $19.2 million in Q1 2022.
- A 5-year average of $19.3 million and a median of $19.4 million in 2023 frame the typical range for Capital Leases.
- The sharpest annual moves came in 2022 and 2026: Capital Leases gained 0.78% in 2022, then slipped 0.18% in 2026.
- Over 5 years, Capital Leases stood at $19.3 million in 2022, then increased by 0.44% to $19.4 million in 2023, then rose by 0.16% to $19.4 million in 2024, then slipped by 0.11% to $19.4 million in 2025, then decreased by 0.08% to $19.3 million in 2026.
- According to Business Quant data, Capital Leases over the past three periods registered $19.3 million, $19.4 million, and $19.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rocket Pharmaceuticals | 380.92 Mn | 380.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.33 Mn |
| Mar 31, 2026 | 19.35 Mn |
| Dec 31, 2025 | 19.36 Mn |
| Sep 30, 2025 | 19.38 Mn |
| Jun 30, 2025 | 19.38 Mn |
| Mar 31, 2025 | 19.38 Mn |
| Dec 31, 2024 | 19.38 Mn |
| Sep 30, 2024 | 19.38 Mn |
| Jun 30, 2024 | 19.37 Mn |
| Mar 31, 2024 | 19.36 Mn |
| Dec 31, 2023 | 19.35 Mn |
| Sep 30, 2023 | 19.34 Mn |
| Jun 30, 2023 | 19.32 Mn |
| Mar 31, 2023 | 19.29 Mn |
| Dec 31, 2022 | 19.27 Mn |
| Sep 30, 2022 | 19.24 Mn |
| Jun 30, 2022 | 19.21 Mn |
| Mar 31, 2022 | 19.18 Mn |
| Dec 31, 2021 | 19.14 Mn |
| Sep 30, 2021 | 19.11 Mn |